ACHN

4:10 pm Achillion Pharma advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, into clinical trial; initiates Phase 2 pilot study with ACH-3102, NS5A Inhibitor, for HCV

moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

The 10 Most Heavily Shorted Bio-Pharma Stocks

moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

3 Biotech Flops of 2013

[at Motley Fool] – 2013 was a great year for the biotech industry as a whole, but Achillion, Prosensa, and Amarin didn’t share the joy. moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV

[at noodls] – NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion to Present at Two Upcoming Investor Conferences

[at noodls] – NEW HAVEN, Conn., March 1, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at two … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock

[at noodls] – NEW HAVEN, Conn., Feb. 21, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock

[at noodls] – NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of $125 million of its common stock. … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion Reports 2012 Fourth Quarter and Year-End Financial Results

[at noodls] – – Conference call and webcast to be held today, February 20th, at 5:00 pm EST – NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here […]